The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 OSI Pharmaceuticals Inc.  (OSIP) Trade Now »     Rate OSIP  -  Discuss OSIP  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:
N/A

** not enough data to be rated 		This Quarter's Sentiment:
All:
90.0%
Top:
100.0%
Rate OSIP:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

OSIP: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Updated Clinical Trial and FDA Decision Calendars Graphic_rating_buy OSIP
Mikerun
73%
 -8.54%
in 234 days
Below is a summary of updates to the BioMedReports.com database of 241 entries included in the FDA and Clinical Trial Calendars.
 
 
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through 3/20/09. The FDA Calendar includes the following information: company name, ticker, decision date, and descrip...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/20/09 Comment


OSI Pharmaceuticals Inc. Graphic_rating_buy OSIP
Foto
62%
 -33.92%
in 433 days
OSI Pharmaceuticals, Inc., a biotechnology company, discovers, develops, and commercializes molecular targeted therapies for oncology, diabetes, and obesity in the United States and internationally. Its flagship product, Tarceva (erlotinib) is a small molecule inhibitor of the epidermal growth factor receptor, which is used for the treatment of advanced non-small cell lung cancer, as well as for the treatment of patients with locally advanced and metastatic pancreatic cancer in combination with the chemotherapy agent, gemcitabine. The company also offers Macugen for the treatment of neovasc...
By  Marian Filo   (-24.55%  risk: aggressive)  09/01/08 Comment


OSIP is a HOLD OSIP
 4 %
 -5.72%
in 869 days

Traders at Palma are Neutral on OSIP

www.palmaresearch.com/default.aspx?viewreport=OSIP

 

By  traderthoughts   (-10.83%  risk: aggressive)  06/23/07 Comment


OSIP is a HOLD OSIP
 4 %
 +0.28%
in 12 days
(closed on 06/23/07)

Traders at Palma are Neutral on OSIP

www.palmaresearch.com/default.aspx?viewreport=OSIP

 

By  traderthoughts   (-10.83%  risk: aggressive)  06/11/07 Comment




From the Blogosphere

As Galleon Investors Flee, Some Tech Stocks Could Suffer
N/A

The spreading Galleon Group insider trading scandal has begun causing problems for some stocks in which the hedge fund operator has large holdings, the Wall Street Journal notes.

The Journal notes that investors have sought to withdraw $1.3 billion of the $3.7 billion in assets managed by the hedge fund group. The WSJ also noted that two large brokerage firms - Bank of America Merrill Lynch and Barclays - have told Galleon they will no longer trade with the firm.

According to StreetSight.net, at June 30 Galleon held more than 2% of the outstanding shares of eight different stocks:

<><><>Applied Ener...
By  Eric Savitz (Barron's)    10/20/09 Comment


Who Will Buy Spectrum Pharmacueticals?
<>There seems to be a lot of speculation on the chances of Spectrum Pharma (SPPI) being acquired over the coming months. I personally don't think it will happen, but there are a few companies that could be interested. Bayer (BYERF.PK) will always be mentioned because of the fact they sell Zevalin in Europe, but Bayer did just divest two oncology drugs to Genzyme (GENZ), Fludara and Leukine, which makes me think that oncology is not where they want to focus their company. Allergan (AGN) should also be mentioned because of their partnership of bladder cancer drug EOquin with Spectrum, the drug...
By  trackseekingalpha   (-14.31%  risk: aggressive)  08/06/09 Comment


OSI Pharmaceutical Gets a Boost from Cancer Drug

By Jon "DRJ" Najarian

<>OSI ChartLung Cancer Drug Advances

OSI Pharmaceutical (OSIP) and Roche subsidiary Genentech (DNA) announced that a pivotal Phase III study of Tarceva met a key secondary endpoint of extending overall survival in patients with advanced lung cancer who received the drug immediately after initial chemotherapy. A statistically significant improvement in overall survival was seen in this final analysis of the total patient population. OSIP and Genentech will present during the 13th World Conference on Lung Cancer to be held July 31 to Aug. 4 in San Francisco. OSIP closed at $28.44 Fri...
By  trackseekingalpha   (-14.31%  risk: aggressive)  07/13/09 Comment


Analyst upgrades, downgrades and initiations: SNDK, POT, BK, ASIA ...

Filed under: Analyst reports, Analyst upgrades and downgrades, Bank of New York (BK), Analyst initiations, SanDisk Corp (SNDK)

Analyst upgrades:
<>
  • Thomas Weisel upgraded SanDisk (NASDAQ: SNDK) to Overweight from Market Weight due to accelerating manufacturing cost declines, potential NAND flash sourcing upside at Toshiba (OTC: TOSBF) and Samsung and an increase in 2H09 demand.
    • <>Oppenheimer upgraded Quality Systems (NASDAQ: QSII) to Perform from Underperform to reflect potential benefits from the stimulus package and channel checks that indicated IT budgets are stabilizing. The firm raise...
    By  Eric Buscemi   (+0.00%)  07/13/09 Comment


    What Happened In The Market Today…3 Feb 09
    Stop
    56%
    What’s Happening In The Market Now..
    <>
  • Stocks popped up at the open this morning after Citigroup (C) announced a $36.5 billion lending plan.
  • Consumers frightened by the prospect of losing their jobs stayed away from auto showrooms again in January and sent U.S. car and truck sales falling 37 percent.
    • <>The National Association of Realtors said buyers stepped in to snap up properties at steep discounts in December, especially in the South and Midwest. Its seasonally adjusted index of pending sales for preowned homes rose 6.3 percent in the final month of the year from revised figures in Nov...
    By  s J   (-17.38%  risk: aggressive)  02/04/09 Comment



    ROCK-STAR INVESTORS
    Rank Name Sharpe Ratio Avg Return Followers
    1 noshoes 21.10 +35.23% 368
    2 Gerald Greene 18.14 +70.19% 206
    3 stockmarketfunding.com 17.66 +25.78% 53
    4 akiralegrand 13.47 +14.32% 61
    5 anup2104 12.13 +69.23% 34


    POPULAR STOCKS
    Symbol Company Name Sentiment
    JNJ Johnson & Johnson
    DRYS DryShips Inc.
    AAPL Apple Computer Inc
    MO Altria Group Inc
    POT Potash Corp. of Saskatchewan Inc.
    KO The CocaCola Company

    TODAY'S HEADLINES

    TODAY'S TOP PICKS

    		 

    StreetInsider.com on OSIP

    Visit streetinsider.com


    Discussion Wall + Add  

    Be the first to start a discussion and earn 2 points.



    More Resources

    Graphic_arrow1 About OSI Pharmaceuticals Inc. - Answers.com

    Graphic_arrow1 Historical Prices - Yahoo

    Graphic_arrow1 Message Boards - BoardCentral.com

    Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




    		IN THE PRESS
    Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch